상세검색
최근 검색어 전체 삭제
다국어입력
즐겨찾기0
학술저널

2023년 FDA 승인 펩타이드 의약품

FDA Approved Peptide Drugs in 2023

  • 66
약학회지 제68권 제2호(2024년).jpg

Peptide drugs generally show high performance in terms of safety, target affinity, and efficacy, but have limitations such as low bioavailability and short half-life. To improve this, new synthetic and analytical techniques have been developed, and the global market for peptide drugs has made great strides in the past few years, with novel peptide drugs being applied to multiple therapeutic areas. In line with this trend, 5 out of 55 new molecular entities (NMEs) approved by the FDA in the year 2023 were peptide drugs, which is an increasing trend in the last few years. In this review article, we will discuss the mechanisms of action and clinical indications, chemical structure and design, and pharmacokinetic perspectives of 6 FDA-approved peptide drugs in 2023 including 5 NMEs.

서 론(Introduction)

본 론(Body)

결 론(Conclusion)

감사의 말씀(Acknowledgment)

Conflict of Interest

References

(0)

(0)

로딩중